CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
|
|
- Monica Hutchinson
- 6 years ago
- Views:
Transcription
1 Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of ) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# ) in the Very High Risk Stratum AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# ; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy) AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B- Lymphoblastic Leukemia AALL1521/Incyte A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitnib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and /or JAK Pathway-Mutant Acute Lymphoblastic Leukemia AALL15P1 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement AALL1621 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# , IND# ) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia AALL1631 AAML1331 AAML1421 AAML1522/ Celgene AAML1531 POETIC International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid A Phase 1/2 Study of CPX-351 (NSC# ; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects From 1 to 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias Page 1 of 5
2 Brain ACNS0332 ACNS0831 ACNS1422 NMTRC ONC POETIC POETIC G Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients Phase I/II Study of Neratininb in children and Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies A Phase I/II Multicenter, Open Label, Dose Escalation Study Of The Safety And Pharmacokinetics Of Cobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors Germ Cell Tumor AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Liver AHEP0731 Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment Long Term Effects ALTE11C1 Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma Page 2 of 5
3 ALTE11C2 Lymphoma AALL0932 AALL1231 AHOD1331 ANHL12P1 C25004 Neuroblastoma ANBL1221 temporarily closed to accrual ANBL1232 NMTRC 010B NMTRC 011 NMTRC 012 NMTRC 014 NMTRC ONC Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) A Phase III Randomized Trial Investigating Bortezomib (NSC# ; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy) A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (chl) in Children and Adolescents A Randomized Phase II study of Brentuximab Vedotin (NSC# ) and Crizotinib (NSC# ) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND # An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# , IND# 61010) or Chimeric Antibody (ch14.18) (NSC# , IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma A Phase I/II Trial of DFMO in Combination with Bortezomib in Patients with Relapsed or Refractory Neuroblastoma A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma Neuroblastoma Maintenance Therapy Trial Using DFMO Page 3 of 5
4 Renal Sarcoma/Rhabdomyosaroma/Osteosarcoma/Ewing's Sarcoma AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# , IND# ) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma AOST1321 Phase II Study of Denosumab, a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma Temporarily Closed to Accrual AOST1421 Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma ARST1321 Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# , IND# ) ARST1431 PI: Becton Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Page 4 of 5
5 NMTRC ONC Solid Tumors ADVL1322/Novartis ADVL1622 POETIC G POETIC POETIC A Phase II Trial of Pazopanib NSC# , IND# in Children with Refractory Solid Tumors Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors A Phase I/II Multicenter, Open Label, Dose Escalation Study Of The Safety And Pharmacokinetics Of Cobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias Phase I/II Study of Neratininb in children and Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies PEDIATRIC MATCH APEC1621SC NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol APEC1621A APEC1621C APEC1621D APEC1621E APEC1621F APEC1621G APEC1621H Phase 2 Subprotocol of LOXO-101 in Patients with Tumors Harboring Actionable NTRK Fusions. Phase 2 Subprotocol of Tazemetostat for Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Phase 2 Subprotocol of LY in Solid Tumors Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes Page 5 of 5
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationPEDIATRIC. BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a COMPANION STUDIES
PEDIATRIC BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients. https://clinicaltrials.gov/ct2/show/nct00392327?term=0332&rank=6
More informationContacts. Catherine Aftandilian, MD, MS Gary Dahl, MD Norman Lacayo, MD. Allison Pribnow, MD Sheri Spunt, MD, MBA
and Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation Contacts General Inquiries: Oncology Christina Baggott, RN, PhD General Inquiries: Hematology Elaine Macasiray, RN AML, ALL Catherine
More informationContacts. Catherine Aftandilian, MD, MS Norman Lacayo, MD Gary Dahl, MD. Sheri Spunt, MD, MBA. Crystal Mackall, MD Kara Davis, DO
and Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation Contacts General Inquiries Baggott, RN, PhD AML, ALL Bone and Soft Tissue Sarcomas, Renal Tumors Catherine Aftandilian, MD, MS,
More informationHem/Onc/BMT Open and Enrolling Clinical Trials
Hem/Onc/BMT Open and Enrolling Clinical Trials PROTOCOL ID DISEASE PROTOCOL TITLE PI ELIGIBILITY CRITERIA Pfizer Apixaban DVT Apixaban B0661037, A Randomized, Open-Label, Active Controlled, Safety and
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
More information5/8/2015. Disclosures. Personalized Medicine & Pediatric Oncology: Is the Future Here Yet? Objectives
Disclosures Personalized Medicine & Pediatric Oncology: Is the Future Here Yet? Richard Drachtman, MD NJAAP Annual Conference May 13, 2015 Research Support: Mast, Astra Zeneca, Jazz, Novartis, Pfizer Objectives
More informationSelected Protocols for the Treatment of Pediatric Cancer and Blood Disorders
Selected Protocols for the Treatment of Pediatric Cancer and Blood Disorders This listing changes frequently. It also does not include most of our Children s Oncology Group (COG) trials. We are part of
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationSarcomas. Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center
Sarcomas Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center Aaron Sugalski, DO Associate Professor of Pediatric Hematology/Oncology Medical Director, UHS Pediatric Blood and Cancer
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationDeclining Childhood and Adolescent Cancer Mortality
Declining Childhood and Adolescent Cancer Mortality Malcolm A. Smith, MD, PhD 1 ; Sean F. Altekruse, DVM, PhD 2 ; Peter C. Adamson, MD 3 ; Gregory H. Reaman, MD 4 ; and Nita L. Seibel, MD 1 BACKGROUND:
More informationOpen Trials as of end of March 2016
EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Cancer Clinical Trials in the Sacramento Area Summer 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.3 3. Gastrointestinal
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 8 COG-AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationOur Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
More informationIntroduction to Pediatric Neoplasms
Introduction to Pediatric Neoplasms F C D S E D U C A T I O N A L W E B C A S T S E R I E S S T E V E N P E A C E, B S, C T R / M A Y R A E S P I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
More informationDiagnosis Place of delivery Proforma
STCYPCNG List of chemotherapy regimens Day Localised Unresectable neuroblastoma (CCLG guidelines) Carbo-Etoposide Etoposide CADO Doxorubin, Vincristine Irinotecan, Irinotecan-TMZ temozolomide Localised
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationPaediatric Strategy Forum A new concept proposed by ACCELERATE
A new concept proposed by ACCELERATE 1 2 s Objective - provide a unique opportunity for interaction between all stakeholders (regulators, pharmaceutical companies, clinical and researcher academics and
More information1/15/2013. Introduction to Pediatric Neoplasms. Program Outline. Introduction
Introduction to Pediatric Neoplasms F C D S E D U C A TI O N A L WE B C A S T S E R I E S ST E VE N P E A C E, B S, C T R / MA Y R A E SP I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationRMS, RMS. (rhabdomyosarcoma,rms) (Intergroup RMS Study Group,IRSG) ( European Pediatric soft tissue sarcomas study group,epssg)
724 2017 10 55 10 Chin J Pediatr, October 2017, Vol.55, No.10 ( CCCG-RMS-2016) (rhabdomyosarcoma,rms), 6.5% [1-3], RMS,, (Intergroup RMS Study Group,IRSG) ( European Pediatric soft tissue sarcomas study
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationXerocept for Control of Tumor or Radiation Mediated Swelling /I-II Mark W. Kieran, MD, PhD
Treatment Area Study Name ID Number/ Phase BRAIN TUMORS Brain Tumor Imaging Recurrent Brain Tumors A Pilot Non-Therapeutic Neuro-Imaging Study of 18F-FLT in Pediatric Patients with Newly Diagnosed Central
More informationAn international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato-oncology clinical management protocols and agreed chemotherapy
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Solid Tumors of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_solid_tumors_childhood
More informationAdvances in paediatric cancer treatment
Review Article Advances in paediatric cancer treatment Federica Saletta 1,2, Michaela S. Seng 2, Loretta M.S. Lau 1,2,3 1 Children s Cancer Research Unit, Kid s Research Institute, The Children s Hospital
More informationOPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationOpen / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone
This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato oncology clinical management protocols and agreed chemotherapy
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationRARE TUMORS OF INFANCY. RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital
RARE TUMORS OF INFANCY RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital OBJECTIVES Review the epidemiology and clinical presentation of soft tissue sarcomas in infancy.
More informationPaediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies. Open. In Development. In Development. Open. Open.
Paediatric Cancer Brain LGG2: Cooperative multicenter study for children and adolescents with Low Grade Glioma GD2: A Phase I/II dose schdule finding study of CH14.18/CHO continuous infusion combined wugt
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationOVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Research in Medical Oncology
Clinical Research in Medical Oncology Adam M. Petrich, MD Northwestern University June 2, 2015 Objectives Why oncology? Why lymphoma? Why clinical research? Discuss various phases and objectives of clinical
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationUK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky
UK Musculoskeletal Oncology: Something for All Ages Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky Pediatric-Type Sarcomas of Bone and Soft Tissue The incidence of sarcoma continues
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationPaediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies
Paediatric Cancer Brain SIOP Ependymoma II; An International Multi Centre Clinical Program for the ependymoma@trials.bham.ac.uk diagnosis and treatment of children, adolescents and young adults with Ependymoma
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationThe Texas Pediatric PDX Core. Peter J. Houghton, Ph.D., Director Greehey Children s Cancer Research Institute UT Health Science Center San Antonio
The Texas Pediatric PDX Core Peter J. Houghton, Ph.D., Director Greehey Children s Cancer Research Institute UT Health Science Center San Antonio GOALS To successfully heterograft and propagate 200-250
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More informationAdvances in haematological malignancies focus on lymphoid disease
Advances in haematological malignancies focus on lymphoid disease Dr Kylie Mason MBBS PhD FRACP FRCPA Haematologist Bone marrow Transplant Physician Clinician Scientist The Royal Melbourne Hospital The
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationSignificant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions
Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Susannah E. Koontz, PharmD, BCOP Clinical Pharmacy & Education Consultant Pediatric Hematology/Oncology and
More informationintolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*
What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationThe Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
More informationShared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)
Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group) January 2013 The NCIN is a UK-wide initiative, working to drive improvements in standards of cancer care and clinical outcomes by improving
More information7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
1 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom and Related Disorders Conditions: Multiple Myeloma; Waldenstrom's ; Smoldering Multiple Myeloma; Lymphoblastic Lymphoma Intervention:
More informationFor Health Professionals Who Care For Cancer Patients EDITOR S CHOICE
Inside This Issue: For Health Professionals Who Care For Cancer s March 2019 Vol. 22 No. 3 Editor s Choice New Programs: Rituximab Protocols in CLL/SLL Updated (LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR,
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationCHILDHOOD CANCERS are rare, accounting for less than
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives By Steven Hirschfeld, Peter T.C. Ho, Malcolm Smith, and Richard Pazdur Purpose: To review the Food and Drug Administration
More informationNational Cancer Drugs Fund List
National Cancer s Fund List (Including list of NICE approved and baseline funded drugs/indications from 1st April 2016 with criteria for use) ver1.95 20-Jul-18 NHS England INFORMATION READER BOX Directorate
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationProduct Visual Guide
Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.
More informationNH Comprehensive Cancer Collaboration Complete List of Open Trials Sorted Alphabetically by Type of Cancer in left column Last Updated June 1, 2017
Type of Cancer Where it is being offered Trial # Description/title For More Information-NCI number link Column1 Column7 ALL CANCER D15154 Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationAntibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma
Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important
More informationCCG-3891 LONG TERM OUTCOME FOR CHILDREN WITH HIGH RISK NEUROBLASTOMA Additional Information on Corrected Overall Survival Results April 10, 2014
Group Chair Peter C. Adamson, M.D. adamson@email.chop.edu Group Vice Chair Susan Blaney, M.D. smblaney@txch.org Chief Operating Officer Elizabeth O Connor, M.P.H. econnor@childrensoncology group.org Chief
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationWorld Health Organization: Essential Medicines and Devices for Cancer:
World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Essential Out-of Hours Cancer Chemotherapy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Essential Out-of Hours Cancer Chemotherapy Version No.: 4.0 Effective From: 27 December 2017 Expiry Date: 27 December 2020 Date Ratified: 19 July
More informationCHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling
CHK1 Inhibitor Prexasertib, LY2606368 MsOH H 2 O Derived from Garrett MD and Collins I 1 ; Thompson R and Eastman A. 2 Drug Discovery Platform: Cancer Cell Signaling A Phase 2 Study of LY2606368 in Patients
More informationCurrent Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review
EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University
More informationHighlights from the 2017 Annual Meeting of the American Society of Hematology
Latest NEWS IN BLOOD CANCER RESEARCH Highlights from the 2017 Annual Meeting of the American Society of Hematology CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series
More information10/7/2014. I have no conflicts of interest I will discuss drugs used for non-fda approved causes
Stuart H. Gold The University of North Carolina at Chapel Hill October 3, 2014 I have no conflicts of interest I will discuss drugs used for non-fda approved causes 1 Pediatric oncology cooperative groups
More informationRituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting
1 Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Conditions: Waldenstrom's ; Waldenstrom Macroglobulinaemia Intervention: Biological: Ofatumumab Sponsor: GlaxoSmithKline Number
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More information